Novartis recognized among world's most sustainable companies in Corporate Knights Global 100
- Details
- Category: Novartis
Novartis has been named among the 2014 Corporate Knights Global 100. Corporate Knights announced the results of its 2014 Global 100 Most Sustainable Corporations in the World (Global 100) index at the World Economic Forum in Davos.
Bristol-Myers Squibb Reports fourth quarter and full year 2013 financial results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model.
Abbott reports fourth-quarter and full-year 2013 results
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2013. Fourth-quarter 2013 worldwide sales of $5.7 billion increased 3.3 percent on an operational basis, driven by Diagnostics and Medical Devices. On a reported basis, sales increased 0.4 percent, including an unfavorable 2.9 percent effect of foreign exchange.
AstraZeneca and Bristol-Myers Squibb Diabetes Alliance provides $5 million grant for American Diabetes Association's Pathway to Stop Diabetes
- Details
- Category: Bristol-Myers Squibb
AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies' U.S. Diabetes Alliance is providing a three-year grant to the American Diabetes Association's Pathway to Stop Diabetes program. The innovative research initiative provides resources and support for a new generation of diabetes researchers and is designed to generate exciting discoveries through excellence, innovation, collaboration and radical thinking.
Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (LSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Tafinlar® (dabrafenib) for treatment of patients with metastatic BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy.
MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
- Details
- Category: AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collaboration and licensing agreement with Immunocore Limited, a privately-held, UK-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.
Bayer and Peking University establish new research center for translational research and drug discovery in Beijing
- Details
- Category: Bayer
Bayer HealthCare and Peking University (PKU), Beijing, China, have signed a comprehensive collaboration agreement on a three-year strategic partnership to promote translational research for drug discovery. Under this agreement, the two partners will establish a joint research center at Peking University under the name Bayer HealthCare/Peking University Center of Translational Research for Drug Discovery (BPC/TRDD).
More Pharma News ...
- GSK adds detailed clinical trial data to multi-sponsor request system
- Bayer plans to acquire Norwegian pharmaceutical company Algeta
- Bristol-Myers Squibb to sell its global diabetes business
- Pfizer settles Viagra® patent litigation with Teva
- Lundbeck and Otsuka to co-develop Lu AF20513, an investigational vaccine against Alzheimer's disease
- FDA Advisory Committee votes on investigational medicine metreleptin
- Multimillion pound investment in UK life sciences research and development